Tag Archives: KRAS

KRAS Made No Difference in Stage III Outcome

Patients with stage III colon cancer didn’t do better or worse if their tumor had mutated KRAS. Studying KRAS in the tumors of about half the patients in a large clinical trial of chemotherapy for stage III colon cancer, researchers found no differences in disease-free, recurrence-free, or overall survival.  This remained true no matter which chemotherapy the patients received.

FDA Approves Labeling Changes for Erbitux and Vectibix to Reflect KRAS Status

The Food and Drug Administration (FDA) has approved labeling changes for Vectibix and Erbitux to reflect studies that found the two drugs are not effective in patients whose tumors have mutated KRAS. The FDA has updated the indication and usage for Vectibix™  (panitumumab) and Erbitux® (cetuximab) to include a statement that: retrospective subset analyses of metastatic or advanced colorectal cancer trials have not shown a treatment benefit for ERBITUX in patients whose tumors had K-ras mutations in codon 12 or 13 and that the use of ERBITUX is not recommended for the treatment of colorectal cancer with these mutations. Retrospective subset analyses of metastatic or advanced colorectal cancer trials have not

ASCO Advises Oncologists: Test for KRAS Mutations

The American Society for Clinical Oncology (ASCO) has published a provisional clinical opinion (PCO) advising doctors to test patients with colorectal cancer for KRAS mutations before treating them with medicines that include Erbitux® (cetuximab) or Vectibix™ (panitumumab). The consensus of experts who reviewed recent research was that patients with metastatic colorectal cancer whose tumors have mutations in the KRAS gene do not benefit from treatment that targets the epidermal growth factor receptor (anti-EGFR therapy).  Patients should be tested for KRAS mutations and, if those mutations are found, not receive anti-EGFR antibodies as part of their treatment.. A PCO, based on expert consensus, is designed to help decision-making for oncologists faced with

Colorectal Cancer News in Brief: April 10

This week we review research on the impacts of colonoscopy screening in Germany, folic acid flour supplementation in Chile, and untreated anxiety and pain during the last months of life on surviving spouses of cancer patients. In the news are reports of colon cancer surgery using a tiny incision in the belly button, requirements for KRAS testing before insurance will pay for Erbitux or Vectibix treatment, and information about how stem cells in the intestinal tract become cancer stem cells, driving the development and progression of colorectal cancer.

KRAS Testing Has Potential to Save Millions in Health Care Costs

Update from the 2009 Gastrointestinal Cancer Symposium Over half a billion dollars could potentially be saved if all patients with colorectal cancer that had spread were tested for the KRAS gene before beginning treatment. Because patients with mutated KRAS in their tumors don’t benefit from treatment with EGFR inhibitors Erbitux® (cetuximab) and Vectibix™ (panitumumab), offering them those drugs is a futile expense.  In addition, trying the drugs delays potentially effective treatment and exposes patients to skin rash and other unnecessary side effects.

NCCN Updates Guidelines to Include KRAS Testing

The National Comprehensive Cancer Network (NCCN) has updated their Clinical Practice Guidelines in Oncology for Colon Cancer to include testing tumors from patients with metastatic colon cancer for the KRAS gene.  The Guidelines also now say that cetuximab (Erbitux®) and panitumumab (Vectibix™) should only be given to patients whose tumors have normal (wild-type) KRAS.

Another Gene Found Linked to Lack of Erbitux/Vectibix Response

Another mutated gene has been discovered that appears to cause resistance to treatment with the EGFR inhibitors Erbitux® (cetuximab) and  Vectibix™ (panitumumab). Only a fraction of patients who receive Erbitux or Vectibix respond to it.  There is now convincing evidence that the 30 to 40 percent of colorectal cancer patients whose tumors have mutated KRAS genes don’t benefit, but what about others who have normal or wild-type KRAS and don’t respond either? Scientists in Italy have found that about 12 percent of wild-type patients have a mutation in their tumor’s BRAF gene, and these patients showed no response to Erbitux or Vectibix.